crefmirlimab

**Crefmirlimab** is an investigational, protein-based anti-human CD8 minibody (antibody fragment) developed primarily for diagnostic imaging of CD8+ T cells in the context of various cancers. By targeting the CD8 antigen (CD8A) present on cytotoxic T lymphocytes, crefmirlimab enables non-invasive, whole-body visualization and quantification of CD8+ immune cell infiltration and dynamics using PET imaging. The most widely used clinical formulation, **zirconium Zr 89 crefmirlimab berdoxam**, involves radiolabeling this minibody with zirconium-89 (^89Zr), allowing precise immune PET for monitoring tumor immune landscapes and guiding immunotherapy assessment. The primary developer is **ImaginAb**. Its main indication is as a diagnostic imaging agent to assess immune response in oncology, with active clinical development in malignant melanoma, renal cell carcinoma, non-small cell lung cancer, and other solid tumors[1][3][4][5][7][9].

Brand names

CD8 ImmunoPETCD-8 ImmunoPETCD 8 ImmunoPET

Other names

zirconium Zr 89 crefmirlimab berdoxam[89Zr]Df-crefmirlimab[89Zr]Df-IAB22M2CCD8 T cell I/O imaging agentCD8 T cell imaging agentCD-8 T cell imaging agentCD 8 T cell imaging agentMinibody CD8 T Cell imaging agent89-Zr CD8 ImmunoPET minibodyZr-89 crefmirlimab berdoxamZr89 crefmirlimab berdoxamZr 89 crefmirlimab berdoxam